| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
208.71(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.39 - $22.2 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
53,265 |
53,265 |
74,223 |
229,905 |
| Total Sell Value |
$339,844 |
$339,844 |
$555,147 |
$3,944,931 |
| Total People Sold |
3 |
3 |
4 |
13 |
| Total Sell Transactions |
3 |
3 |
5 |
43 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Balachandran Madhavan |
Director |
– • – |
2023-02-27 |
4 |
S |
$19.99 |
$7,676 |
D/D |
(384) |
19,573 |
|
46% |
|
| Dolmetsch Ricardo |
President, R&D |
• – – |
2023-02-27 |
4 |
S |
$19.58 |
$135,964 |
D/D |
(6,944) |
170,082 |
|
46% |
|
| Caloz Pierre |
Chief Operating Officer |
• – – |
2023-02-27 |
4 |
S |
$19.59 |
$85,608 |
D/D |
(4,365) |
114,125 |
|
46% |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2023-02-27 |
4 |
S |
$19.86 |
$388,313 |
D/D |
(19,526) |
476,285 |
|
46% |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2023-02-27 |
4 |
S |
$20.10 |
$197,462 |
D/D |
(9,824) |
136,796 |
|
46% |
|
| Kaye Jack |
Director |
– • – |
2023-02-27 |
4 |
S |
$19.99 |
$7,676 |
D/D |
(384) |
27,699 |
|
46% |
|
| Meek David D. |
Director |
– • – |
2023-02-27 |
4 |
S |
$19.71 |
$7,667 |
D/D |
(389) |
16,071 |
|
46% |
|
| Springhorn Jeremy P. |
Director |
– • – |
2023-02-27 |
4 |
S |
$20.41 |
$7,837 |
D/D |
(384) |
19,573 |
|
46% |
|
| Soteropoulos Paula |
Director |
– • – |
2023-02-27 |
4 |
S |
$19.97 |
$7,668 |
D/D |
(384) |
15,998 |
|
46% |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
37,400 |
146,620 |
|
- |
|
| Caloz Pierre |
Chief Operating Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
46,700 |
118,490 |
|
- |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
121,500 |
495,811 |
|
- |
|
| Dolmetsch Ricardo |
President, R&D |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
46,700 |
177,026 |
|
- |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,830 |
374,311 |
|
- |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,040 |
97,692 |
|
- |
|
| Dolmetsch Ricardo |
President, R&D |
• – – |
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,920 |
130,326 |
|
- |
|
| Klemt Christian |
Chief Financial Officer |
• – – |
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,040 |
109,220 |
|
- |
|
| Caloz Pierre |
Chief Operating Officer |
• – – |
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
2,920 |
71,790 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2023-01-18 |
4 |
AS |
$22.59 |
$135,540 |
D/D |
(6,000) |
16,382 |
|
-12% |
|
| Soteropoulos Paula |
Director |
– • – |
2023-01-18 |
4 |
OE |
$5.37 |
$32,220 |
D/D |
6,000 |
22,382 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2022-12-14 |
4 |
AS |
$23.43 |
$89,034 |
D/D |
(3,800) |
16,382 |
|
-18% |
|
| Soteropoulos Paula |
Director |
– • – |
2022-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,800 |
20,182 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2022-12-13 |
4 |
AS |
$23.45 |
$70,350 |
D/D |
(3,000) |
16,382 |
|
-17% |
|
| Soteropoulos Paula |
Director |
– • – |
2022-12-13 |
4 |
OE |
$5.37 |
$16,110 |
D/D |
3,000 |
19,382 |
|
- |
|
| Kapusta Matthew C |
CEO, Managing Director |
• • – |
2022-12-09 |
4 |
S |
$22.44 |
$149,181 |
D/D |
(6,648) |
368,481 |
|
11% |
|
336 Records found
|
|
Page 2 of 14 |
|
|
0.01 (0.21%) 
